Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Judd

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Molecular Genetics and Metabolism|July 30, 2018
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreL R Ranganath, M Khedr, A M Milan, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Data in Brief|September 29, 2018
Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinoneR Griffin, E E Psarelli, T F Cox, et al.
Journal of Medicinal Chemistry|March 31, 2006
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Andrew J Souers, Thomas J Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activityAndrew S Judd, Andrew J Souers, Dariusz Wodka, et al.
Journal of Medicinal Chemistry|January 11, 2008
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorGang Zhao, Andrew J Souers, Martin Voorbach, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylaminesAndrew J Souers, Rajesh R Iyengar, Andrew S Judd, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
American Journal of Botany|May 27, 2011
Angiosperm phylogeny: 17 genes, 640 taxaDouglas E Soltis, Stephen A Smith, Nico Cellinese, et al.
Journal of Medicinal Chemistry|October 27, 2006
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safetyJohn K Lynch, Jennifer C Freeman, Andrew S Judd, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Molecular Genetics and Metabolism|July 30, 2018
Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria CentreL R Ranganath, M Khedr, A M Milan, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Data in Brief|September 29, 2018
Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinoneR Griffin, E E Psarelli, T F Cox, et al.
Journal of Medicinal Chemistry|March 31, 2006
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Andrew J Souers, Thomas J Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activityAndrew S Judd, Andrew J Souers, Dariusz Wodka, et al.
Journal of Medicinal Chemistry|January 11, 2008
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorGang Zhao, Andrew J Souers, Martin Voorbach, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylaminesAndrew J Souers, Rajesh R Iyengar, Andrew S Judd, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
American Journal of Botany|May 27, 2011
Angiosperm phylogeny: 17 genes, 640 taxaDouglas E Soltis, Stephen A Smith, Nico Cellinese, et al.
Journal of Medicinal Chemistry|October 27, 2006
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safetyJohn K Lynch, Jennifer C Freeman, Andrew S Judd, et al.
Pageof 9